Overall, these findings highlight evidence that CB-PIC induces apoptosis through the Warburg effect via inhibition of STAT3 and pyruvate signaling as a potent anti-STAT3 candidate (Figure 6), since there are no studies to show clinical impact in HCC patients yet, though Napabucasin is the only candidate into phase III trials in advanced colcorectal cancer patients among other STAT3 therapies [30]. This evidence concerns the gene STAT3 and hepatocellular carcinoma.